BLAInjectionInjectablePriority Review
Approved
Feb 2026
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
LOARGYS (pegzilarginase-nbln) by Medica Corp is arg1-d is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. First approved in 2026.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOARGYS (pegzilarginase-nbln) is an injectable enzyme replacement therapy for arginase 1 deficiency (ARG1-D), a rare inherited metabolic disorder. It provides exogenous arginase 1 enzyme activity to reduce elevated plasma arginine by converting it to urea and ornithine. The drug addresses a critical unmet need in this ultra-rare monogenic disease with no approved alternatives.
Growth
As a newly launched orphan drug with no competitors, the brand team will focus on payer education, rare disease identification, and patient registry building in a constrained but stable patient population.
Mechanism of Action
ARG1-D is an inherited metabolic disease characterized by deficiency of the arginase 1 enzyme and associated with the persistent elevation of plasma arginine. LOARGYS provides an exogenous source of the deficient human arginase 1 enzyme activity in patients with ARG1-D and reduces plasma arginine…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on LOARGYS offers career exposure to orphan drug commercialization, ultra-rare disease engagement, and payer strategy in a niche but specialized market. Team size will be modest given the patient population, but roles carry high visibility within rare disease networks and can accelerate expertise in rare metabolic disorders.
Rare Disease Brand Manager
Worked on LOARGYS at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.